Real‐World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape
Journal of the Peripheral Nervous System · 2025
DOI: 10.1111/jns.70047 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the Peripheral Nervous System, 2025. Verfasst von Luis Querol und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Diagnostic Errors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune‐mediated syndrome characterized by progressive muscle weakness and sensory impairment. Clinical similarities with other neuropathies can cause misdiagnoses and delayed diagnoses. Additionally, a large proportion of patients appropriately treated according to current guidelines still show residual disability. This real‐world study aimed to characterize a global cohort of patients with CIDP.
Methods
Data were drawn from the Adelphi CIDP Disease Specific Programme, a cross‐sectional survey with retrospective data collection, conducted in China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States between September 2022 and April 2023. Neurologists and neuromuscular specialists reported on patient demographic and clinical characteristics at the time of the survey. Patients self‐reported treatment satisfaction, disease control, and health‐related outcome measures.
Results
Overall, 164 physicians provided data for 1056 patients, with 428 (40.5%) providing self‐reported data. Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%). Overall, initial misdiagnosis occurred in 37.2% of patients, with a median (interquartile range) diagnostic delay of 6.0 (3.0–12.0) months. Maintenance therapy was prescribed for 81.6% of patients, with corticosteroid use ranging from 25.7% in the United States to 80.0% in China. Some patients were dissatisfied by treatment outcomes (11.0%) and symptom control (12.2%). Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.
Interpretation
Diagnostic delay and misdiagnoses were common occurrences across typical CIDP and variant CIDP. Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
- Janssen-Cilag Ltd, A Johnson & Johnson Company, High Wycombe, UK.
- Janssen-Cilag SpA, A Johnson & Johnson Company, Milan, Italy.
- Adelphi Real World, Bollington, UK.
- Janssen-Cilag, A Johnson & Johnson Company, Strasbourg, France.
ORCID-Profile: Luis Querol
Zitieren
APA
Querol, L., Rinaldi, S., Borsi, A., Boggia, G. M., de Courcy, J., Taylor, Y., Wright, J., Karmous, W., Noel, W., Gary, C., & Meyer Zu Hörste, G. (2025). Real‐World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70047
Vancouver
Querol L, Rinaldi S, Borsi A, Boggia GM, de Courcy J, Taylor Y, et al. Real‐World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape. Journal of the Peripheral Nervous System. 2025. doi:10.1111/jns.70047
BibTeX
@article{Querol2025,
author = {Querol, Luis and Rinaldi, Simon and Borsi, Andras and Boggia, Giorgio Maria and de Courcy, Jonathan and Taylor, Yasmin and Wright, Jack and Karmous, Wisam and Noel, Wim and Gary, Charlotte and Meyer Zu Hörste, Gerd},
title = {Real‐World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape},
journal = {Journal of the Peripheral Nervous System},
year = {2025},
doi = {10.1111/jns.70047}
}
EUVIMED